AOD-9604 + BPC-157 Stack Protocol
The AOD-9604 + BPC-157 stack combines two of the most well-researched peptides for complementary body recomposition and healing benefits. AOD-9604 (hGH fragment 176-191) stimulates lipolysis and inhibits lipogenesis without affecting blood glucose or IGF-1 levels, while BPC-157 (Body Protection Compound-15) promotes systemic tissue repair, accelerates wound healing, reduces inflammation, and supports gut health through multiple pathways including VEGF upregulation and NO system modulation. Together they provide targeted fat loss with enhanced recovery, making this stack particularly popular for subjects seeking body recomposition with concurrent injury rehabilitation.
Protocol Overview
- Compounds
- AOD-9604 (hGH fragment 176-191) + BPC-157
- Category
- Fat Loss / Tissue Repair Stack
- Mechanism
- AOD-9604: lipolysis via beta-3 adrenergic pathway | BPC-157: tissue repair via VEGF, NO, FAK-paxillin pathway modulation
- Route
- Subcutaneous (can combine in one syringe)
- Frequency
- 1-2x daily
- Cycle Length
- 8-12 weeks on, 4 weeks off
Dosing Protocol
| Protocol | AOD-9604 | BPC-157 | Frequency | Duration |
|---|---|---|---|---|
| Standard | 300 mcg | 250 mcg | 1x daily (AM fasted) | 8-12 weeks |
| Enhanced Repair | 300 mcg (AM) | 250 mcg 2x (AM + PM) | 2x daily BPC | 8-12 weeks |
| Advanced | 300 mcg 2x (AM + PM) | 250 mcg 2x (AM + PM) | 2x daily both | 8-12 weeks |
Key principle: AOD-9604 requires fasted administration (no food 30 min before/after). Both peptides can be drawn into the same syringe. For injury focus, inject BPC-157 near the injury site; for systemic benefits, inject in abdominal fat.
Reconstitution Guide
AOD-9604 (5mg vial)
- Diluent: 2mL bacteriostatic water
- Concentration: 2.5mg/mL
- 300mcg dose: 12 units on insulin syringe
- Vial yield: ~16 doses at 300mcg
BPC-157 (5mg vial)
- Diluent: 2mL bacteriostatic water
- Concentration: 2.5mg/mL
- 250mcg dose: 10 units on insulin syringe
- Vial yield: 20 doses at 250mcg
- Combined draw: 22 units total for both
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness (mild, transient)
- Mild headache during first few days (uncommon)
- Slight drowsiness with BPC-157 (some subjects)
Both peptides have excellent safety profiles. AOD-9604 does not affect blood glucose, IGF-1, or cortisol. BPC-157 is derived from gastric juice and has shown no toxicity in research.
Precautions
- AOD-9604: take fasted for optimal fat loss
- BPC-157: theoretical concern with active cancer (angiogenesis)
- Monitor blood glucose if diabetic
- Not recommended during pregnancy
Stacking Additions
Add to This Stack
- CJC-1295/Ipamorelin: GH support at night for enhanced recomp
- 5-Amino-1MQ: NNMT inhibition for additional fat metabolism
- TB-500: Enhanced tissue repair (loading phase)
- L-Carnitine: Fatty acid transport support
Popular Expansions
- Full Recomp: AOD/BPC + CJC/Ipa at night + fasted cardio
- Injury Recovery: AOD/BPC + TB-500 2mg 2x/wk
- Metabolic: AOD/BPC + 5-Amino-1MQ 100mg/day oral
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Metabolic | Fasting glucose, insulin, HbA1c, lipid panel | Baseline, Week 6, Week 12 |
| Inflammation | hs-CRP, ESR | Baseline, Week 6, Week 12 |
| Liver Function | ALT, AST, GGT | Baseline, Week 12 |
| Body Composition | DEXA scan, waist circumference | Baseline, Week 12 |
Related Tools & Resources
